Renown Regional Medical Center

Clinical research site in Reno, Nevada · 1155 MILL STREET, RENO, NV 89502-1474 · (775) 982-4100

As of September 2026, 82 paid clinical trials are recruiting at Renown Regional Medical Center in Reno, Nevada. Active studies at this site cover conditions such as Malignant Solid Neoplasm, Acute Myeloid Leukemia and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

New trial at Renown Regional Medical Center? We'll email you when one opens.

Recruiting clinical trials at Renown Regional Medical Center (82)

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma

62 locations incl. Aurora

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07392892·Phase 2, Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

for Clostridoides Difficile Associated Disease

140 locations incl. Athens

Sponsor: Pfizer

Sex: All·Age: 65+·Accepts healthy volunteers

Code: NCT07282665·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

200 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for Non-small Cell Carcinoma

218 locations incl. Alabaster

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07144280·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

for Carcinoma, Hepatocellular

41 locations incl. Irvine

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227012·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for Breast Neoplasms

60 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06966700·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

for Early Breast Cancer

83 locations incl. Birmingham

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

for Colon Adenocarcinoma

39 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06997497·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

37 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

37 locations incl. Chandler

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06568939·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

for Cachexia

83 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06989437·Phase 2, Phase 3·Recruiting·Listed May 2025

Apply to this trial

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

for Non-Small Cell Lung Cancer

26 locations incl. Irvine

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07100080·Phase 2, Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

for Antineutrophil Cytoplasmic Antibody-associated Vasculitis

58 locations incl. Scottsdale

Sponsor: Amgen

Sex: All·Age: 18 - 100

Code: NCT06072482·Phase 4·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for Non Small Cell Lung Cancer

44 locations incl. Little Rock

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312137·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

for Non-small Cell Lung Cancer

40 locations incl. Mobile

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06561386·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

for Hypertension

33 locations incl. Birmingham

Sponsor: SoniVie Inc.

Sex: All·Age: 22 - 75

Code: NCT06559891·Recruiting·Listed Aug 2024

Apply to this trial

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

for Pulmonary Hypertension

32 locations incl. Birmingham

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT06911632·Recruiting·Listed Apr 2025

Apply to this trial

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

for Liver Neoplasms

27 locations incl. Fullerton

Sponsor: HistoSonics, Inc.

Sex: All·Age: 22+

Code: NCT06486454·Recruiting·Listed Jul 2024

Apply to this trial

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

for Metastatic Breast Cancer

31 locations incl. Scottsdale

Sponsor: LeonaBio

Sex: All·Age: 18+

Code: NCT05696626·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

for Lung Cancer Diagnosis

36 locations incl. Los Angeles

Sponsor: Freenome Holdings Inc.

Sex: All·Age: 50+

Code: NCT06122077·Recruiting·Listed Nov 2023

Apply to this trial

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

for HR+/HER2- Breast Cancer

36 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT07492641·Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

for Metastatic Breast Cancer

8 locations incl. La Jolla

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT03424005·Phase 1, Phase 2·Recruiting·Listed Feb 2018

Apply to this trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

for Lymphoma

20 locations incl. Duarte

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06084936·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

for Non-small Cell Lung Cancer (NSCLC)

10 locations incl. Phoenix

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06170788·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

25 locations incl. Anchorage

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06899126·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

for Non-Squamous Non-Small Cell Lung Cancer

13 locations incl. Chandler

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07005102·Phase 2, Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

SPYRAL GEMINI Pilot Study

for Hypertension

12 locations incl. Stanford

Sponsor: Medtronic Vascular

Sex: All·Age: 18 - 80

Code: NCT06907147·Recruiting·Listed Apr 2025

Apply to this trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for PIK3CA Mutation

23 locations incl. Tucson

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05216432·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

for Non-small Cell Lung Cancer

12 locations incl. Sacramento

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07513376·Phase 3·Recruiting·Listed Apr 2026

Apply to this trial

Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based Initiative Component

for Lung Cancer Screening

13 locations incl. Greenville

Sponsor: Timothy Mullett

Sex: All·Age: 18 - 100

Code: NCT07682597·Recruiting·Listed Jul 6, 2026

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1100 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Family Communications After Genetic Testing

for Colon Adenocarcinoma

290 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07143487·Recruiting·Listed Aug 2025

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

915 locations incl. Fairhope

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

779 locations incl. Issaquah

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for Intracranial Meningioma

446 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT02523014·Phase 2·Recruiting·Listed Aug 2015

Apply to this trial

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

for Advanced Esophageal Adenocarcinoma

632 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

for Metastatic Small Intestinal Adenocarcinoma

399 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04205968·Phase 2·Recruiting·Listed Dec 2019

Apply to this trial

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

for Smoldering Plasma Cell Myeloma

484 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT03937635·Phase 3·Recruiting·Listed May 2019

Apply to this trial

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

for Acute Lymphoblastic Leukemia

618 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 40 - 75·Accepts healthy volunteers

Code: NCT05334069·Recruiting·Listed Apr 2022

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

535 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting·Listed Sep 2023

Apply to this trial

Showing the 40 most relevant of 82 recruiting trials at this site. Browse all with filters →

Get new-trial alerts for Renown Regional Medical Center

We'll email you whenever a new clinical trial starts recruiting at this research site in Reno, NV. Unsubscribe anytime.

More research sites in Reno

Saint Mary's Regional Medical Center (19 trials)
Sierra Eye Associates (19 trials)
Radiation Oncology Associates (9 trials)
Renown Health Medical Oncology (6 trials)
Cancer Care Specialists (6 trials)
Renown Office of Clinical Research (4 trials)
Renown Regional Medical Center-Renown Health Medical Oncology (4 trials)
Center of Hope (3 trials)
The Center Of Hope (3 trials)
Advanced Research Institute - Reno (2 trials)

Is this your research site?

This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.

Explore more

Paid clinical trials in Reno, NV · Nevada clinical trials